Amicogen, Inc. (KOSDAQ:092040)
South Korea
· Delayed Price · Currency is KRW 1,279.00
-61.00 (-4.55%)
Mar 9, 2026, 3:30 PM KST
Amicogen Revenue
Amicogen had revenue of 10.14B KRW in the quarter ending September 30, 2025, a decrease of -74.58%. This brings the company's revenue in the last twelve months to 87.97B, down -43.52% year-over-year. In the year 2024, Amicogen had annual revenue of 173.60B with 8.57% growth.
Revenue (ttm)
87.97B
Revenue Growth
-43.52%
P/S Ratio
1.02
Revenue / Employee
372.74M
Employees
236
Market Cap
90.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 173.60B | 13.70B | 8.57% |
| Dec 31, 2023 | 159.90B | 15.61B | 10.82% |
| Dec 31, 2022 | 144.30B | 19.41B | 15.55% |
| Dec 31, 2021 | 124.88B | 9.02B | 7.79% |
| Dec 31, 2020 | 115.86B | 675.18M | 0.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IMB Dx | 4.26B |
| GeneOne Life Science | 30.90B |
| Oncocross | 884.68M |
| CG Invites | 18.12B |
| ORIENT BIO | 59.09B |
| ENCell | 5.91B |
| Macrogen | 179.98B |
| Vaxcell-Bio Therapeutics | 1.90B |